Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours

肿瘤免疫控制需要通过干扰素依赖性细胞周期调节通路诱导肿瘤细胞衰老。

阅读:5
作者:Ellen Brenner # ,Barbara F Schörg # ,Fatima Ahmetlić # ,Thomas Wieder ,Franz Joachim Hilke ,Nadine Simon ,Christopher Schroeder ,German Demidov ,Tanja Riedel ,Birgit Fehrenbacher ,Martin Schaller ,Andrea Forschner ,Thomas Eigentler ,Heike Niessner ,Tobias Sinnberg ,Katharina S Böhm ,Nadine Hömberg ,Heidi Braumüller ,Daniel Dauch ,Stefan Zwirner ,Lars Zender ,Dominik Sonanini ,Albert Geishauser ,Jürgen Bauer ,Martin Eichner ,Katja J Jarick ,Andreas Beilhack ,Saskia Biskup ,Dennis Döcker ,Dirk Schadendorf ,Leticia Quintanilla-Martinez ,Bernd J Pichler ,Manfred Kneilling ,Ralph Mocikat ,Martin Röcken

Abstract

Immune checkpoint blockade (ICB)-based or natural cancer immune responses largely eliminate tumours. Yet, they require additional mechanisms to arrest those cancer cells that are not rejected. Cytokine-induced senescence (CIS) can stably arrest cancer cells, suggesting that interferon-dependent induction of senescence-inducing cell cycle regulators is needed to control those cancer cells that escape from killing. Here we report in two different cancers sensitive to T cell-mediated rejection, that deletion of the senescence-inducing cell cycle regulators p16Ink4a/p19Arf (Cdkn2a) or p21Cip1 (Cdkn1a) in the tumour cells abrogates both the natural and the ICB-induced cancer immune control. Also in humans, melanoma metastases that progressed rapidly during ICB have losses of senescence-inducing genes and amplifications of senescence inhibitors. Metastatic cells also resist CIS. Such genetic and functional alterations are infrequent in metastatic melanomas regressing during ICB. Thus, activation of tumour-intrinsic, senescence-inducing cell cycle regulators is required to stably arrest cancer cells that escape from eradication.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。